Comparison of two clinical severity scoring systems in two multi-center, developing country rotavirus vaccine trials in Africa and Asia

Simple item page
dc.contributor.authorLewis, K.D.C.
dc.contributor.authorDallas, M.J.
dc.contributor.authorVictor, J.C.
dc.contributor.authorCiarlet, M.
dc.contributor.authorMast, T.C.
dc.contributor.authorJi, M.
dc.contributor.authorArmah, G.
dc.contributor.authorZaman, K.
dc.contributor.authorFerraro, A.
dc.contributor.authorNeuzil, K.M.
dc.date.accessioned2019-01-17T15:18:53Z
dc.date.available2019-01-17T15:18:53Z
dc.date.issued2012-04
dc.description.abstractBackground: Clinical severity scoring systems are used in rotavirus vaccine efficacy and effectiveness studies to define the primary endpoint, severe rotavirus gastroenteritis (RVGE). Understanding how scoring systems perform in diverse settings is critical for proper design and interpretation. This investigation aims to understand how the Vesikari scoring system (VSS) and Clark scoring system (CSS) categorize severe disease among children under 2 years of age using data from two Phase III efficacy trials conducted in five developing countries in Africa and Asia. Methods: Signs and symptoms were collected on trial participants who presented to a medical facility with study-defined gastroenteritis. Severity scores were calculated using pre-established VSS and CSS criteria and compared to identify differences in the proportions of severe RVGE within regions and sites, and by gender and age. Results: In Africa and Asia, 40.6% and 56.0% of rotavirus-positive episodes were severe according to the VSS, while 9.5% and 6.3% of episodes were severe according to the CSS (Fisher's Exact, p≤ 0.001). Using the mean scores in these trials (VSS: ≥10 Africa, ≥11 Asia; CSS: Africa and Asia ≥10) as the severity thresholds, agreement between scoring system severity classifications improved substantially within each region (Africa: kappa = 0.67; Asia: kappa = 0.78) as compared to the original severity classification (Africa: kappa = 0.27; Asia: kappa = 0.10). Using the mean score, 17.1% and 9.5% of severe VSS cases in Africa and Asia, respectively, were classified as not severe according to the CSS and 14.7% and 9.5% of severe CSS cases in Africa and Asia were classified as not severe according to the VSS. Conclusion: The two scoring systems performed differently among developing country populations in Africa and Asia, with the VSS classifying more cases as severe in both regions. One accurate and reliable scoring system should be developed and implemented for all trials so that results may be more comparable. © 2011 Elsevier Ltd.en_US
dc.identifier.otherVolume 30, Supplement 1, Pages A159-A166
dc.identifier.otherhttps://doi.org/10.1016/j.vaccine.2011.07.126
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/26884
dc.language.isoenen_US
dc.publisherVaccineen_US
dc.subjectClark scoring systemen_US
dc.subjectGastroenteritisen_US
dc.subjectRotavirusen_US
dc.subjectSeverity scoreen_US
dc.subjectVaccine efficacyen_US
dc.subjectVesikari scoring systemen_US
dc.titleComparison of two clinical severity scoring systems in two multi-center, developing country rotavirus vaccine trials in Africa and Asiaen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Comparison of two clinical severity scoring systems in two multi-center, developing country rotavirus vaccine trials in Africa and Asia.pdf
Size:
448.09 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Electron Microscopy Department